RT Journal Article
T1 Anti-IL6-Receptor Tocilizumab in Refractory and Noninfectious Uveitic Cystoid Macular Edema: Multicenter Study of 25 Patients.
A1 Vegas-Revenga, Nuria
A1 Calvo-Rio, Vanesa
A1 Mesquida, Marina
A1 Adan, Alfredo
A1 Hernandez, Maria Victoria
A1 Beltran, Emma
A1 Valls-Pascual, Elia
A1 Diaz-Valle, David
A1 Diaz-Cordoves, Gisela
A1 Hernandez-Garfella, Marisa
A1 Martinez-Costa, Lucia
A1 Calvo, Inmaculada
A1 Atanes, Antonio
A1 Linares, Luis F
A1 Modesto, Consuelo
A1 Gonzalez-Vela, Carmen
A1 Demetrio-Pablo, Rosalia
A1 Aurrecoechea, Elena
A1 Cordero, Miguel
A1 Dominguez-Casas, Lucia C
A1 Atienza-Mateo, Belen
A1 Martin-Varillas, Jose Luis
A1 Loricera, Javier
A1 Palmou-Fontana, Natalia
A1 Hernandez, Jose L
A1 Gonzalez-Gay, Miguel A
A1 Blanco, Ricardo
K1 Sarcoidosis
K1 Tomography, Optical Coherence
K1 Treatment Outcome
K1 Uveitis
K1 Visual Acuity
AB Cystoid macular edema (CME) is a leading cause of blindness. This study assessed the efficacy and safety of tocilizumab (TCZ) in refractory CME. Retrospective case series. Patients with CME secondary to noninfectious uveitis who had inadequate response to corticosteroids and at least 1 conventional immunosuppressive drug, and in most cases to other biological agents, were studied. CME was defined as central retinal thickness greater than 300 μm. The primary outcome measure was macular thickness. Intraocular inflammation, best-corrected visual acuity (BCVA), and corticosteroid-sparing effect were also analyzed. A total of 25 patients (mean ± standard deviation age 33.6 ± 18.9 years; 17 women) with CME were assessed. Underlying diseases associated with uveitis-related CME are juvenile idiopathic arthritis (n = 9), Behçet disease (n = 7), birdshot retinochoroidopathy (n = 4), idiopathic (n = 4), and sarcoidosis (n = 1). The ocular patterns were panuveitis (n = 9), anterior uveitis (n = 7), posterior uveitis (n = 5), and intermediate uveitis (n = 4). Most patients had CME in both eyes (n = 24). TCZ was used in monotherapy (n = 11) or combined with conventional immunosuppressive drugs. Regardless of the underlying disease, compared to baseline, a statistically significant improvement in macular thickness (415.7 ± 177.2 vs 259.1 ± 499.5 μm; P = .00009) and BCVA (0.39 ± 0.31 vs 0.54 ± 0.33; P = .0002) was obtained, allowing us to reduce the daily dose of prednisone (15.9 ± 13.6 mg/day vs 3.1 ± 2.3 mg/day; P = .002) after 12 months of therapy. Remission was achieved in 14 patients. Only minor side effects were observed after a mean follow-up of 12.7 ± 8.34 months. Macular thickness is reduced following administration of TCZ in refractory uveitis-related CME.
PB Elsevier
YR 2018
FD 2018-12-29
LK http://hdl.handle.net/10668/13435
UL http://hdl.handle.net/10668/13435
LA en
NO Vegas-Revenga N, Calvo-Río V, Mesquida M, Adán A, Hernández MV, Beltrán E, et al. Anti-IL6-Receptor Tocilizumab in Refractory and Noninfectious Uveitic Cystoid Macular Edema: Multicenter Study of 25 Patients. Am J Ophthalmol. 2019 Apr;200:85-94
DS RISalud
RD Apr 6, 2025